Actavis Eyes Acquisitions In The Middle East And Niche Products In The U.S.

Possibly acquiring development expertise in biosimilars from the Swiss firm BioPartners is one of several strategic moves that newly appointed chief executive Claudio Albrecht is now making at the generics company Actavis